When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.

That's why we have released our Free Precious Metals Investment Guide.

Robert Kraft Biography and Net Worth

Director of Medpace

Mr. Kraft has served as the Chief Financial Officer and Treasurer of The Hillman Companies, Inc. and The Hillman Group since November 2017. Mr. Kraft served as the Executive Vice President of CVS Health Corporation and the President of Omnicare, Inc., CVS’s long-term care business, from August 2015 to September 2017. From September 2012 to August 2015, Mr. Kraft served as Senior Vice President and Chief Financial Officer of Omnicare, Inc., and from November 2010 to September 2012, he served as Senior Vice President, Finance of Omnicare, Inc. Before joining Omnicare, Inc., Mr. Kraft was an audit partner at PricewaterhouseCoopers LLP, where he worked for 18 years.

Mr. Kraft received his Bachelor’s Degree in Accounting from the University of Dayton. Mr. Kraft was chosen as a director because of his significant financial and accounting experience from his background as an audit partner at PricewaterhouseCoopers LLP and his experience as an executive of a public company

What is Robert O. Kraft's net worth?: The estimated net worth of Robert O. Kraft is at least $74,434.84 as of August 14th, 2023. Mr. Kraft owns 188 shares of Medpace stock worth more than $74,435 as of April 27th. This net worth approximation does not reflect any other investments that Mr. Kraft may own. Learn More about Robert O. Kraft's net worth.
How do I contact Robert O. Kraft?: The corporate mailing address for Mr. Kraft and other Medpace executives is 5375 MEDPACE WAY, CINCINNATI OH, 45227. Medpace can also be reached via phone at (513) 579-9911 and via email at [email protected]. Learn More on Robert O. Kraft's contact information.
Has Robert O. Kraft been buying or selling shares of Medpace?: Robert O. Kraft has not been actively trading shares of Medpace during the last ninety days. Most recently, Robert O. Kraft sold 13,782 shares of the business's stock in a transaction on Monday, August 14th. The shares were sold at an average price of $265.67, for a transaction totalling $3,661,463.94. Following the completion of the sale, the director now directly owns 188 shares of the company's stock, valued at $49,945.96. Learn More on Robert O. Kraft's trading history.
Who are Medpace's active insiders?: Medpace's insider roster includes Kevin Brady (CFO), Susan Burwig (VP), Stephen Ewald (General Counsel), Jesse Geiger (CFO), Ashley Keating (Director), Tom King (Director), Robert Kraft (Director), and August Troendle (CEO). Learn More on Medpace's active insiders.
Are insiders buying or selling shares of Medpace?: In the last twelve months, insiders at the sold shares 24 times. They sold a total of 809,782 shares worth more than $239,436,337.21. The most recent insider tranaction occured on March, 15th when VP Susan E Burwig sold 102 shares worth more than $41,106.00. Insiders at Medpace own 20.3% of the company. Learn More about insider trades at Medpace.
Information on this page was last updated on 3/15/2024.

Robert O. Kraft Insider Trading History at Medpace

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/14/2023	Sell	13,782	$265.67	$3,661,463.94	188

Robert O. Kraft Buying and Selling Activity at Medpace

Medpace Company Overview

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Today's Range

Now: $395.93

$388.88

$397.17

50 Day Range

MA: $397.83

$372.00

$413.31

2 Week Range

Now: $395.93

$189.30

$421.00

Volume

144,670 shs

Average Volume

240,981 shs

Market Capitalization

$12.27 billion

P/E Ratio

40.36

Dividend Yield

N/A

Beta

1.38

The Gold Grab of the Century

From Colonial Metals | Ad